Skip to main
REPL
REPL logo

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc. has seen an increase in the probability of approval for its lead product, RP1, in combination with Opdivo for patients with advanced melanoma, rising to 95%. The company's proprietary in-house manufacturing capabilities enable competitive cost of goods sold, enhancing profitability potential. Additionally, the encouraging clinical data, including an overall response rate of approximately 33% and a median duration of response of 21.6 months, underscores the strong commercial prospects for Replimune's product pipeline, particularly with a potential market entry slated for later this year.

Bears say

Replimune Group Inc. is projected to incur a net loss of $2.99 per share for fiscal 2025, reflecting a worsening financial outlook compared to previous estimates. The company's risks are exacerbated by uncertainties surrounding the efficacy and safety of its lead product candidate, RP1, including challenges in clinical trials and potential regulatory hurdles. Furthermore, there is a concerning possibility of medium- to long-term dilution risk, which could negatively impact shareholder value if development efforts are halted due to safety or efficacy issues.

REPL has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 13 analysts, REPL has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.